A Phase I/II Study to Determine the Maximum Tolerated Doses of Oral Topotecan, Carboplatin and Paclitaxel Administered Every 21 Days to Patients With Epithelial Ovarian Cancer Stages IIb, IIc, III and IV
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Topotecan (Primary) ; Carboplatin; Paclitaxel
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Aug 2013 Biomarkers information updated
- 15 Aug 2005 New trial record.